A 38-year-old woman from Bangalore presents with a 6-month history of burning pain in the right V1 (ophthalmic) distribution, accompanied by conjunctival injection and lacrimation. Pain is constant, not lancinating, and does not respond to carbamazepine 800 mg/day. MRI brain shows no mass or demyelination. She has a history of recurrent oral ulcers and uveitis. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis **Key Point:** This is **secondary trigeminal neuralgia** (atypical presentation) in the context of **Behçet disease**. The constellation of recurrent oral ulcers, uveitis, and V1 neuropathy with poor response to standard TN therapy is highly suggestive. ## Differential Diagnosis of Trigeminal Neuropathy | Cause | Features | Key Finding | |-------|----------|-------------| | **Classic TN** | Lancinating, trigger-evoked, V2/V3 > V1 | Normal MRI; responds to carbamazepine | | **Behçet Disease** | Burning, constant; V1 common; oral/genital ulcers, uveitis | HLA-B51+; systemic vasculitis | | **MS-related TN** | Bilateral or atypical; young age; progressive | MRI shows demyelinating lesions | | **Herpes zoster** | Vesicular rash; dermatomal; acute onset | Rash precedes or accompanies pain | | **Tumor/compression** | Progressive; neurological deficit; imaging positive | MRI/MRA abnormal | | **Sarcoidosis** | Bilateral; systemic symptoms; ACE elevated | Chest imaging, serum ACE | **High-Yield:** Behçet disease is an HLA-B51–associated vasculitis endemic in the Mediterranean, Middle East, and Asia. Neurological involvement (neuro-Behçet) occurs in 5–10% of cases and presents as TN, brainstem syndrome, or myelitis. ## Red Flags for Secondary TN **Warning:** This patient has THREE red flags: 1. **Atypical pain quality:** Burning (not lancinating). 2. **Poor response to carbamazepine:** 800 mg/day is a therapeutic dose; lack of response suggests secondary cause. 3. **Systemic features:** Recurrent oral ulcers + uveitis + trigeminal neuropathy = Behçet disease until proven otherwise. ## Diagnostic Approach ```mermaid flowchart TD A[Trigeminal Neuropathy]:::outcome --> B{Classic presentation<br/>+ normal MRI?}:::decision B -->|Yes| C[Classic TN:<br/>Start carbamazepine]:::action B -->|No| D[Atypical features or<br/>poor drug response?]:::decision D -->|Yes| E[Secondary TN:<br/>Investigate cause]:::action E --> F{Systemic symptoms?}:::decision F -->|Oral ulcers,<br/>uveitis, genital ulcers| G[Test HLA-B51]:::action F -->|Demyelinating lesions| H[Treat as MS-TN]:::action F -->|Chest symptoms| I[Check serum ACE,<br/>chest imaging]:::action G --> J[Behçet Disease:<br/>Rheumatology referral]:::action ``` ## Management of Neuro-Behçet **Clinical Pearl:** Neuro-Behçet requires immunosuppression, not just symptomatic TN therapy. First-line agents include: - **Corticosteroids** (high-dose IV methylprednisolone for acute, then oral taper). - **Azathioprine** or **mycophenolate mofetil** (steroid-sparing agents). - **TNF-α inhibitors** (infliximab) for refractory cases. Carbamazepine alone is insufficient; the underlying vasculitis must be treated. **Tip:** Always ask about oral ulcers, genital ulcers, ocular symptoms, and skin lesions in any patient with atypical TN. A positive HLA-B51 in the right clinical context is diagnostic of Behçet disease. [cite:Harrison 21e Ch 380; Robbins & Cotran 10e Ch 28]